Cipla, Eli Lilly and Company enter into strategic partnership in India

04 Oct 2021 Evaluate

Cipla and Eli Lilly and Company (India) -- wholly owned subsidiary of Eli Lilly and Company have entered into strategic partnership in India to enhance the reach of Lilly’s Diabetes products -- Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide).  As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products -- Humalog & Trulicity to Cipla, subject to all regulatory approvals.

Lilly will continue to maintain its existing operating model for the remaining portfolio of products. Cipla will leverage its capabilities and robust distribution strengths to engage healthcare professionals and expand access to these treatments for patients who need them.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1507.30 15.90 (1.07%)
31-Dec-2025 15:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1272.00
Cipla 1507.30
Zydus Lifesciences 912.75
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×